Teacher Retirement System of Texas Increases Stake in Disc Medicine, Inc. (NASDAQ:IRON)

Teacher Retirement System of Texas boosted its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 8.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,857 shares of the company’s stock after buying an additional 396 shares during the period. Teacher Retirement System of Texas’ holdings in Disc Medicine were worth $308,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of IRON. Geode Capital Management LLC raised its position in shares of Disc Medicine by 17.6% in the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock worth $23,333,000 after acquiring an additional 70,983 shares in the last quarter. State Street Corp raised its holdings in Disc Medicine by 39.7% in the third quarter. State Street Corp now owns 827,910 shares of the company’s stock worth $40,683,000 after purchasing an additional 235,115 shares in the last quarter. Verition Fund Management LLC purchased a new position in Disc Medicine during the third quarter valued at $589,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Disc Medicine by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 160,554 shares of the company’s stock valued at $7,890,000 after buying an additional 19,401 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Disc Medicine by 123.7% in the 3rd quarter. Barclays PLC now owns 40,145 shares of the company’s stock worth $1,972,000 after buying an additional 22,202 shares during the period. 83.70% of the stock is owned by institutional investors.

Disc Medicine Trading Down 5.0 %

IRON stock opened at $47.15 on Wednesday. The stock’s 50 day simple moving average is $54.20 and its 200 day simple moving average is $56.21. Disc Medicine, Inc. has a 12-month low of $25.64 and a 12-month high of $68.73. The stock has a market capitalization of $1.63 billion, a PE ratio of -11.85 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.08. On average, research analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on IRON shares. Wedbush reissued an “outperform” rating and set a $90.00 price objective (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Stifel Nicolaus boosted their price target on Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. TD Cowen began coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating on the stock. Scotiabank lifted their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a report on Tuesday, January 21st. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $93.80.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total value of $470,625.00. Following the completion of the sale, the insider now owns 14,035 shares of the company’s stock, valued at approximately $880,696.25. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $87,873.80. Following the transaction, the chief operating officer now directly owns 40,555 shares in the company, valued at $2,213,491.90. The trade was a 3.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 369,190 shares of company stock worth $20,118,719. Company insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.